Neovacs S.A Valor contable por acción
¿Qué es el Valor contable por acción de Neovacs S.A?
El Valor contable por acción de Neovacs S.A. es 0.00
¿Cuál es la definición de Valor contable por acción?
El valor en libros por acción es el activo de una empresa menos el pasivo dividido por el número de acciones en circulación.
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Valor contable por acción de compañías en Sector Health Care en EURONEXT en comparadas con Neovacs S.A
¿Qué hace Neovacs S.A?
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Empresas con valor contable por acción similar a Neovacs S.A
- Cybergun S.A tiene Valor contable por acción de 0.00
- The GO2 People tiene Valor contable por acción de 0.00
- Rhythm Biosciences tiene Valor contable por acción de 0.00
- Orion Metals tiene Valor contable por acción de 0.00
- Clever Leaves tiene Valor contable por acción de 0.00
- Independent Oil & Gas Plc tiene Valor contable por acción de 0.00
- Neovacs S.A tiene Valor contable por acción de 0.00
- Environmental Clean Technologies tiene Valor contable por acción de 0.00
- MJ tiene Valor contable por acción de 0.00
- Intra tiene Valor contable por acción de 0.00
- Key Petroleum tiene Valor contable por acción de 0.00
- CF Finance Acquisition II tiene Valor contable por acción de 0.00
- RMG tiene Valor contable por acción de 0.00